510(k) device
SeptiCyte LAB
Immunexpress, Inc. · Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE, Class II) · First FDA decision Feb 17, 2017, newest Feb 17, 2017Sepsis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "SeptiCyte LAB"
MAUDE reports
0
Brand "SeptiCyte LAB", since 2015
PubMed studies
12
Mentioning "SeptiCyte LAB"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SeptiCyte LAB
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- SeptiCyte LAB510(k)
K163260 · Decided Feb 17, 2017 · 88 days after receipt
Device type: Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40470WPS Insurance CorporationUpdated Sep 17, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40429Palmetto GBAUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40433CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40435Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "SeptiCyte LAB", any status and sponsor, newest update first.
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT06507423 · 15 participants · Start Aug 1, 2024 · Primary completion Sep 1, 2024
Device: Septicyte Lab Test pre operative; Septicyte Lab Test post operative · For: Acute Mesenteric Ischemia; Sepsis Bacterial; Intra-abdominal Infection and 1 more
Sites: Nancy, France
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SeptiCyte LAB", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PRE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SeptiCyte LAB"[tiab]. The summary above synthesizes these.
- Profile of the SeptiCyteࡊ LAB gene expression assay to diagnose infection in critically ill patients.
Verboom DM, Koster-Brouwer ME, Varkila MRJ, et al. · Expert Rev Mol Diagn · 2019Research Support, Non-U.S. Gov't, Review
- Diagnosing sepsis in the ICU: Comparison of a gene expression signature to pre-existing biomarkers.
Denny KJ, Lea RA, Lindell-Innes R, et al. · J Crit Care · 2023Research Support, Non-U.S. Gov't
- A pilot study of a novel molecular host response assay to diagnose infection in patients after high-risk gastro-intestinal surgery.
Verboom DM, Koster-Brouwer ME, Ruurda JP, et al. · J Crit Care · 2019Research Support, Non-U.S. Gov't
- Benchmarking Sepsis Gene Expression Diagnostics Using Public Data.
Sweeney TE, Khatri P · Crit Care Med · 2017
- Diagnostic Accuracy of a Host Gene Expression Signature That Discriminates Clinical Severe Sepsis Syndrome and Infection-Negative Systemic Inflammation Among Critically Ill Children.
Zimmerman JJ, Sullivan E, Yager TD, et al. · Crit Care Med · 2017Observational Study
- Putative mRNA Biomarkers for the Eradication of Infection in an Equine Experimental Model of Septic Arthritis.
Koziy RV, Bracamonte JL, Katselis GS, et al. · Vet Sci · 2024
- Validation of diagnostic gene sets to identify critically ill patients with sepsis.
Maslove DM, Shapira T, Tyryshkin K, et al. · J Crit Care · 2019Research Support, Non-U.S. Gov't, Validation Study
- Transcriptional pathways of terminal differentiation in high- and low-density blood granulocytes in sepsis.
Guenther T, Coulibaly A, Velásquez SY, et al. · J Inflamm (Lond) · 2024
- Validation of a Novel Molecular Host Response Assay to Diagnose Infection in Hospitalized Patients Admitted to the ICU With Acute Respiratory Failure.
Koster-Brouwer ME, Verboom DM, Scicluna BP, et al. · Crit Care Med · 2018Research Support, Non-U.S. Gov't
- Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.
Miller RR, Lopansri BK, Burke JP, et al. · Am J Respir Crit Care Med · 2018Multicenter Study, Observational Study
- A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts.
McHugh L, Seldon TA, Brandon RA, et al. · PLoS Med · 2015Observational Study, Research Support, N.I.H., Extramural
- Erratum: Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.
Am J Respir Crit Care Med · 2020Published Erratum
Other devices of this type
Also filed under product code PRE.
- SeptiCyte RAPIDImmunexpress, Inc. · 510(k) 2023
- TriVerityInflammatix, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.